Traws Pharma (0T20) Stock Price & Analysis
0T20 Stock Chart & Stats
- Day’s Range
- EUR 6.40 - EUR 6.60
- 52-Week Range
- EUR 6.40 - EUR 6.60
- Previous Close
- EUR 6.60
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 4.07M
- Enterprise Value
- EUR 8.37M
- Total Cash (Recent Filing)
- EUR 3.13M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
A debt-free balance sheet reduces mandatory interest and principal payments, preserving flexibility while the company advances clinical programs. This lowers refinancing exposure and allows available capital to be directed toward research, regulatory work, and other operating needs.
Flexible Financing Access
The equity facility gives Traws a committed mechanism to raise capital as needed for product development and working capital. Although issuance may dilute shareholders, access to staged financing can extend the runway for clinical execution and corporate operations.
Lead Antiviral Program Advancing
Progress toward a Phase 2a study represents a meaningful development milestone for the lead antiviral candidate. Advancing through regulatory and clinical stages could improve the pipeline’s strategic value and create future opportunities if efficacy and safety are demonstrated.
Bears Say
Negative Shareholders' Equity
Negative equity signals that accumulated losses or write-downs have exceeded the company’s capital base, limiting financial resilience. It can constrain funding flexibility, increase dependence on new capital, and leave less balance-sheet support for continued clinical investment.
Persistent Cash Burn
Consistently negative operating and free cash flow shows that the business is not self-funding its activities. Continued cash burn increases reliance on equity or other external financing, potentially limiting strategic flexibility and exposing the pipeline to funding availability.
No Current Revenue And Regulatory Hurdles
With no current revenue, Traws depends on successful development and financing rather than an established commercial base. The FDA clinical hold and required toxicology resubmission add execution hurdles that could delay clinical progress and postpone any path to operating revenue.
Traws Pharma News
0T20 FAQ
What was Traws Pharma’s price range in the past 12 months?
What is Traws Pharma’s market cap?
When is Traws Pharma’s upcoming earnings report date?
How were Traws Pharma’s earnings last quarter?
Is Traws Pharma overvalued?
Does Traws Pharma pay dividends?
What is Traws Pharma’s EPS estimate?
How many shares outstanding does Traws Pharma have?
What happened to Traws Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Traws Pharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Traws Pharma
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Iain D. Dukes
- Employees
- 7
- Website
- www.trawspharma.com
- Address
- 12 Penns Trail, Newtown, PA, 18940, US
Traws Pharma (0T20) Earnings & Revenues
0T20 Earnings Call
Earnings Call SentimentNeutral
The call balanced meaningful scientific and financing progress against important regulatory and liquidity risks. Positives include a $60M contingent financing package, robust preclinical data, a next-gen tablet with ~30% higher exposure supporting once-monthly prophylaxis, an approved Australian bridging study and plans for a U.K. human challenge trial. Key negatives are a low year-end cash balance ($3.8M), an FDA clinical hold on the IND for toxicology concerns that could materially delay U.S. development, and dependence on milestone warrants and one-time accounting items for near-term financial stability. Overall, the update conveys cautious optimism but highlights significant execution and regulatory risks that must be resolved to fully realize the program’s potential.
View all DE:0T20 earnings summaries0T20 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 7 |
| Technical Analysis | 1 | 1 | 3 |
| Moving Averages | 4 | 4 | 4 |
